The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
Identifieur interne : 003B76 ( PubMed/Corpus ); précédent : 003B75; suivant : 003B77The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
Auteurs : Rohtesh S. Mehta ; Antonio Di Stasi ; Borje S. Andersson ; Yago Nieto ; Roy Jones ; Marcos De Lima ; Chitra Hosing ; Uday Popat ; Partow Kebriaei ; Betul Oran ; Amin Alousi ; Katayoun Rezvani ; Muzaffar Qazilbash ; Qaiser Bashir ; Catherine Bollard ; Laurence Cooper ; Laura Worth ; Priti Tewari ; Ian Mcniece ; Kaci Willhelm ; Richard Champlin ; Elizabeth J. ShpallSource :
- Clinical lymphoma, myeloma & leukemia [ 2152-2669 ] ; 2014.
English descriptors
- KwdEn :
- Adolescent, Adult, Antineoplastic Agents (therapeutic use), Child, Child, Preschool, Cord Blood Stem Cell Transplantation (methods), Fetal Blood (transplantation), Granulocyte Precursor Cells (drug effects), Hematologic Neoplasms (drug therapy), Hematologic Neoplasms (therapy), Humans, Infant, Middle Aged, Neoplasm Recurrence, Local (prevention & control), Whole-Body Irradiation (methods), Young Adult.
- MESH :
- chemical , therapeutic use : Antineoplastic Agents.
- drug effects : Granulocyte Precursor Cells.
- drug therapy : Hematologic Neoplasms.
- methods : Cord Blood Stem Cell Transplantation, Whole-Body Irradiation.
- prevention & control : Neoplasm Recurrence, Local.
- therapy : Hematologic Neoplasms.
- transplantation : Fetal Blood.
- Adolescent, Adult, Child, Child, Preschool, Humans, Infant, Middle Aged, Young Adult.
Abstract
Cord blood transplantation is being used with increasing frequency for patients with high-risk hematologic malignancies. Myeloablative preparative regimens provide antitumor efficacy and facilitate engraftment but are associated with higher morbidity and nonrelapse mortality rates than nonablative regimens. We evaluated 3 sequential myeloablative regimens in the cord blood transplant setting. Regimen 1 (melphalan, fludarabine, and thiotepa) produced prompt engraftment and minimal engraftment failure but was associated with a high nonrelapse mortality rate. Regimen 2 (busulfan and fludarabine) was very well tolerated but was associated with a high rate of engraftment failure and relapse. Regimen 3 (busulfan, clofarabine, fludarabine, and low-dose total body irradiation given 9 days after the chemotherapy) was associated with a low rate of engraftment failure but was logistically difficult to administer. Finally, regimen 3 that included the total body irradiation given immediately after the chemotherapy was well tolerated, with prompt engraftment and tumor control. This latter regimen appears to be effective in preliminary studies and warrants further evaluation.
DOI: 10.1016/j.clml.2013.08.006
PubMed: 24169268
Links to Exploration step
pubmed:24169268Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.</title><author><name sortKey="Mehta, Rohtesh S" sort="Mehta, Rohtesh S" uniqKey="Mehta R" first="Rohtesh S" last="Mehta">Rohtesh S. Mehta</name><affiliation><nlm:affiliation>Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: mehtars@upmc.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Di Stasi, Antonio" sort="Di Stasi, Antonio" uniqKey="Di Stasi A" first="Antonio" last="Di Stasi">Antonio Di Stasi</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Andersson, Borje S" sort="Andersson, Borje S" uniqKey="Andersson B" first="Borje S" last="Andersson">Borje S. Andersson</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Nieto, Yago" sort="Nieto, Yago" uniqKey="Nieto Y" first="Yago" last="Nieto">Yago Nieto</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, Roy" sort="Jones, Roy" uniqKey="Jones R" first="Roy" last="Jones">Roy Jones</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="De Lima, Marcos" sort="De Lima, Marcos" uniqKey="De Lima M" first="Marcos" last="De Lima">Marcos De Lima</name><affiliation><nlm:affiliation>Case Western University, Cleveland, OH.</nlm:affiliation></affiliation></author><author><name sortKey="Hosing, Chitra" sort="Hosing, Chitra" uniqKey="Hosing C" first="Chitra" last="Hosing">Chitra Hosing</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Popat, Uday" sort="Popat, Uday" uniqKey="Popat U" first="Uday" last="Popat">Uday Popat</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Kebriaei, Partow" sort="Kebriaei, Partow" uniqKey="Kebriaei P" first="Partow" last="Kebriaei">Partow Kebriaei</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Oran, Betul" sort="Oran, Betul" uniqKey="Oran B" first="Betul" last="Oran">Betul Oran</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Alousi, Amin" sort="Alousi, Amin" uniqKey="Alousi A" first="Amin" last="Alousi">Amin Alousi</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Rezvani, Katayoun" sort="Rezvani, Katayoun" uniqKey="Rezvani K" first="Katayoun" last="Rezvani">Katayoun Rezvani</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Qazilbash, Muzaffar" sort="Qazilbash, Muzaffar" uniqKey="Qazilbash M" first="Muzaffar" last="Qazilbash">Muzaffar Qazilbash</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Bashir, Qaiser" sort="Bashir, Qaiser" uniqKey="Bashir Q" first="Qaiser" last="Bashir">Qaiser Bashir</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Bollard, Catherine" sort="Bollard, Catherine" uniqKey="Bollard C" first="Catherine" last="Bollard">Catherine Bollard</name><affiliation><nlm:affiliation>Center for Cell & Gene Therapy, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, Laurence" sort="Cooper, Laurence" uniqKey="Cooper L" first="Laurence" last="Cooper">Laurence Cooper</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Worth, Laura" sort="Worth, Laura" uniqKey="Worth L" first="Laura" last="Worth">Laura Worth</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Tewari, Priti" sort="Tewari, Priti" uniqKey="Tewari P" first="Priti" last="Tewari">Priti Tewari</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Mcniece, Ian" sort="Mcniece, Ian" uniqKey="Mcniece I" first="Ian" last="Mcniece">Ian Mcniece</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Willhelm, Kaci" sort="Willhelm, Kaci" uniqKey="Willhelm K" first="Kaci" last="Willhelm">Kaci Willhelm</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Champlin, Richard" sort="Champlin, Richard" uniqKey="Champlin R" first="Richard" last="Champlin">Richard Champlin</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Shpall, Elizabeth J" sort="Shpall, Elizabeth J" uniqKey="Shpall E" first="Elizabeth J" last="Shpall">Elizabeth J. Shpall</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24169268</idno><idno type="pmid">24169268</idno><idno type="doi">10.1016/j.clml.2013.08.006</idno><idno type="wicri:Area/PubMed/Corpus">003B76</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.</title><author><name sortKey="Mehta, Rohtesh S" sort="Mehta, Rohtesh S" uniqKey="Mehta R" first="Rohtesh S" last="Mehta">Rohtesh S. Mehta</name><affiliation><nlm:affiliation>Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: mehtars@upmc.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Di Stasi, Antonio" sort="Di Stasi, Antonio" uniqKey="Di Stasi A" first="Antonio" last="Di Stasi">Antonio Di Stasi</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Andersson, Borje S" sort="Andersson, Borje S" uniqKey="Andersson B" first="Borje S" last="Andersson">Borje S. Andersson</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Nieto, Yago" sort="Nieto, Yago" uniqKey="Nieto Y" first="Yago" last="Nieto">Yago Nieto</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, Roy" sort="Jones, Roy" uniqKey="Jones R" first="Roy" last="Jones">Roy Jones</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="De Lima, Marcos" sort="De Lima, Marcos" uniqKey="De Lima M" first="Marcos" last="De Lima">Marcos De Lima</name><affiliation><nlm:affiliation>Case Western University, Cleveland, OH.</nlm:affiliation></affiliation></author><author><name sortKey="Hosing, Chitra" sort="Hosing, Chitra" uniqKey="Hosing C" first="Chitra" last="Hosing">Chitra Hosing</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Popat, Uday" sort="Popat, Uday" uniqKey="Popat U" first="Uday" last="Popat">Uday Popat</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Kebriaei, Partow" sort="Kebriaei, Partow" uniqKey="Kebriaei P" first="Partow" last="Kebriaei">Partow Kebriaei</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Oran, Betul" sort="Oran, Betul" uniqKey="Oran B" first="Betul" last="Oran">Betul Oran</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Alousi, Amin" sort="Alousi, Amin" uniqKey="Alousi A" first="Amin" last="Alousi">Amin Alousi</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Rezvani, Katayoun" sort="Rezvani, Katayoun" uniqKey="Rezvani K" first="Katayoun" last="Rezvani">Katayoun Rezvani</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Qazilbash, Muzaffar" sort="Qazilbash, Muzaffar" uniqKey="Qazilbash M" first="Muzaffar" last="Qazilbash">Muzaffar Qazilbash</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Bashir, Qaiser" sort="Bashir, Qaiser" uniqKey="Bashir Q" first="Qaiser" last="Bashir">Qaiser Bashir</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Bollard, Catherine" sort="Bollard, Catherine" uniqKey="Bollard C" first="Catherine" last="Bollard">Catherine Bollard</name><affiliation><nlm:affiliation>Center for Cell & Gene Therapy, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, Laurence" sort="Cooper, Laurence" uniqKey="Cooper L" first="Laurence" last="Cooper">Laurence Cooper</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Worth, Laura" sort="Worth, Laura" uniqKey="Worth L" first="Laura" last="Worth">Laura Worth</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Tewari, Priti" sort="Tewari, Priti" uniqKey="Tewari P" first="Priti" last="Tewari">Priti Tewari</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Mcniece, Ian" sort="Mcniece, Ian" uniqKey="Mcniece I" first="Ian" last="Mcniece">Ian Mcniece</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Willhelm, Kaci" sort="Willhelm, Kaci" uniqKey="Willhelm K" first="Kaci" last="Willhelm">Kaci Willhelm</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Champlin, Richard" sort="Champlin, Richard" uniqKey="Champlin R" first="Richard" last="Champlin">Richard Champlin</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author><author><name sortKey="Shpall, Elizabeth J" sort="Shpall, Elizabeth J" uniqKey="Shpall E" first="Elizabeth J" last="Shpall">Elizabeth J. Shpall</name><affiliation><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical lymphoma, myeloma & leukemia</title><idno type="eISSN">2152-2669</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Antineoplastic Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Cord Blood Stem Cell Transplantation (methods)</term><term>Fetal Blood (transplantation)</term><term>Granulocyte Precursor Cells (drug effects)</term><term>Hematologic Neoplasms (drug therapy)</term><term>Hematologic Neoplasms (therapy)</term><term>Humans</term><term>Infant</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (prevention & control)</term><term>Whole-Body Irradiation (methods)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Granulocyte Precursor Cells</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hematologic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cord Blood Stem Cell Transplantation</term><term>Whole-Body Irradiation</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hematologic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Fetal Blood</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Infant</term><term>Middle Aged</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cord blood transplantation is being used with increasing frequency for patients with high-risk hematologic malignancies. Myeloablative preparative regimens provide antitumor efficacy and facilitate engraftment but are associated with higher morbidity and nonrelapse mortality rates than nonablative regimens. We evaluated 3 sequential myeloablative regimens in the cord blood transplant setting. Regimen 1 (melphalan, fludarabine, and thiotepa) produced prompt engraftment and minimal engraftment failure but was associated with a high nonrelapse mortality rate. Regimen 2 (busulfan and fludarabine) was very well tolerated but was associated with a high rate of engraftment failure and relapse. Regimen 3 (busulfan, clofarabine, fludarabine, and low-dose total body irradiation given 9 days after the chemotherapy) was associated with a low rate of engraftment failure but was logistically difficult to administer. Finally, regimen 3 that included the total body irradiation given immediately after the chemotherapy was well tolerated, with prompt engraftment and tumor control. This latter regimen appears to be effective in preliminary studies and warrants further evaluation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24169268</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>27</Day></DateCreated><DateCompleted><Year>2014</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2152-2669</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical lymphoma, myeloma & leukemia</Title><ISOAbbreviation>Clin Lymphoma Myeloma Leuk</ISOAbbreviation></Journal><ArticleTitle>The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.</ArticleTitle><Pagination><MedlinePgn>e1-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clml.2013.08.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2152-2650(13)00397-2</ELocationID><Abstract><AbstractText>Cord blood transplantation is being used with increasing frequency for patients with high-risk hematologic malignancies. Myeloablative preparative regimens provide antitumor efficacy and facilitate engraftment but are associated with higher morbidity and nonrelapse mortality rates than nonablative regimens. We evaluated 3 sequential myeloablative regimens in the cord blood transplant setting. Regimen 1 (melphalan, fludarabine, and thiotepa) produced prompt engraftment and minimal engraftment failure but was associated with a high nonrelapse mortality rate. Regimen 2 (busulfan and fludarabine) was very well tolerated but was associated with a high rate of engraftment failure and relapse. Regimen 3 (busulfan, clofarabine, fludarabine, and low-dose total body irradiation given 9 days after the chemotherapy) was associated with a low rate of engraftment failure but was logistically difficult to administer. Finally, regimen 3 that included the total body irradiation given immediately after the chemotherapy was well tolerated, with prompt engraftment and tumor control. This latter regimen appears to be effective in preliminary studies and warrants further evaluation.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Rohtesh S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: mehtars@upmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Stasi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Borje S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieto</LastName><ForeName>Yago</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lima</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Case Western University, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosing</LastName><ForeName>Chitra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popat</LastName><ForeName>Uday</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kebriaei</LastName><ForeName>Partow</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oran</LastName><ForeName>Betul</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alousi</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezvani</LastName><ForeName>Katayoun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qazilbash</LastName><ForeName>Muzaffar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bashir</LastName><ForeName>Qaiser</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollard</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Cell & Gene Therapy, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worth</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tewari</LastName><ForeName>Priti</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNiece</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willhelm</LastName><ForeName>Kaci</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Champlin</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shpall</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 CA148600-02</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA061508</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA061508-18</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA148600</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 RP100469</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR000369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000371</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Lymphoma Myeloma Leuk</MedlineTA><NlmUniqueID>101525386</NlmUniqueID><ISSNLinking>2152-2669</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2008 Jun;14(6):672-84</RefSource><PMID Version="1">18489993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Jul;11(7):653-60</RefSource><PMID Version="1">20558104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Pharmacol. 2011 Jan 15;81(2):222-32</RefSource><PMID Version="1">20933509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900</RefSource><PMID Version="1">20946966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2011 Aug;17(8):1255-60</RefSource><PMID Version="1">21220032</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2011 Sep;17(9):1327-34</RefSource><PMID Version="1">21232621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2012 Apr;18(4):565-74</RefSource><PMID Version="1">21875503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2012 Oct;47(10):1287-93</RefSource><PMID Version="1">22327127</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hematology Am Soc Hematol Educ Program. 2012;2012:215-22</RefSource><PMID Version="1">23233584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Dec 13;367(24):2305-15</RefSource><PMID Version="1">23234514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2008 May;14(5):591-4</RefSource><PMID Version="1">18410902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98</RefSource><PMID Version="1">18158965</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Oct 15;110(8):3064-70</RefSource><PMID Version="1">17569820</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2007 Sep;13(9):1022-30</RefSource><PMID Version="1">17697964</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Feb 1;105(3):1343-7</RefSource><PMID Version="1">15466923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Nov 25;351(22):2265-75</RefSource><PMID Version="1">15564543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 Aug 1;104(3):865-72</RefSource><PMID Version="1">15090449</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2000 Sep;26(5):463-70</RefSource><PMID Version="1">11019834</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2001;7(4):208-15</RefSource><PMID Version="1">11349807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 Aug 1;104(3):857-64</RefSource><PMID Version="1">15073038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 1999 Nov;24(9):947-52</RefSource><PMID Version="1">10556952</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036101" MajorTopicYN="N">Cord Blood Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005312" MajorTopicYN="N">Fetal Blood</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042381" MajorTopicYN="N">Granulocyte Precursor Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014916" MajorTopicYN="N">Whole-Body Irradiation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS549252</OtherID><OtherID Source="NLM">PMC3913126</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Conditioning regimen</Keyword><Keyword MajorTopicYN="N">Hematologic malignancies</Keyword><Keyword MajorTopicYN="N">Stem cell transplant</Keyword><Keyword MajorTopicYN="N">Total body irradiation</Keyword><Keyword MajorTopicYN="N">Treatment related mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24169268</ArticleId><ArticleId IdType="pii">S2152-2650(13)00397-2</ArticleId><ArticleId IdType="doi">10.1016/j.clml.2013.08.006</ArticleId><ArticleId IdType="pmc">PMC3913126</ArticleId><ArticleId IdType="mid">NIHMS549252</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003B76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24169268
|texte= The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24169268" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |